Clinical Trial Results:
Phase II Study of Dasatinib (BMS-354825) for Androgen-Deprived Progressive Prostate Cancer
+ Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 2.0 dated 15-Aug-06)
Summary
|
|
EudraCT number |
2006-002205-31 |
Trial protocol |
FR IT |
Global completion date |
18 Oct 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Dec 2016
|
First version publication date |
24 Dec 2016
|
Other versions |
|
Summary report(s) |
CA180-085_Addendum_Synopsis CA180-085_Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.